
Fortress Biotech, Inc. (NASDAQ:FBIO – Free Report) – Equities researchers at HC Wainwright issued their Q4 2026 EPS estimates for Fortress Biotech in a research report issued to clients and investors on Tuesday, November 17th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings per share of ($0.15) for the quarter.
Fortress Biotech (NASDAQ:FBIO – Get Free Report) last issued its quarterly earnings data on Friday, November 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.04. The company had revenue of $19.16 million during the quarter, compared to analysts’ expectations of $21.57 million. Fortress Biotech had a net margin of 143.04% and a return on equity of 61.84%.
Several other research analysts also recently commented on FBIO. Weiss Ratings downgraded shares of Fortress Biotech from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 23rd. Wall Street Zen cut shares of Fortress Biotech from a “strong-buy” rating to a “hold” rating in a report on Saturday, August 15th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $17.00.
Check Out Our Latest Stock Report on Fortress Biotech
Fortress Biotech Stock Performance
NASDAQ FBIO opened at $1.82 on Wednesday. Fortress Biotech has a 1 year low of $1.64 and a 1 year high of $4.53. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.93 and a quick ratio of 3.83. The stock has a market capitalization of $61.41 million, a PE ratio of 0.79 and a beta of 1.27. The company’s 50 day simple moving average is $2.10 and its two-hundred day simple moving average is $2.71.
Institutional Trading of Fortress Biotech
A number of large investors have recently modified their holdings of FBIO. Marshall Wace LLP purchased a new position in shares of Fortress Biotech during the third quarter worth about $462,000. Squarepoint Ops LLC bought a new position in shares of Fortress Biotech in the second quarter worth approximately $47,000. Finally, Renaissance Technologies LLC raised its stake in Fortress Biotech by 22.8% in the first quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company’s stock valued at $278,000 after purchasing an additional 18,490 shares in the last quarter. Institutional investors own 96.51% of the company’s stock.
Fortress Biotech Company Profile
Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.
See Also
- Five stocks we like better than Fortress Biotech
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
